Glimsentro-MV2 Tablet SR is a combination oral hypoglycemic agent formulated with Glimepiride (2mg), Metformin (500mg), and Voglibose (0.2mg) designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the intestines, leading to a reduction in postprandial hyperglycemia. The sustained-release (SR) formulation ensures a gradual release of active ingredients, promoting better glycemic control with reduced dosing frequency and improved patient compliance. Glimsentro-MV2 is indicated as adjunctive therapy to diet and exercise for patients inadequately controlled on monotherapy or dual therapy. It is essential to monitor blood glucose levels regularly to assess efficacy and adjust dosage accordingly. Caution is advised in patients with renal or hepatic impairment, and potential adverse effects include hypoglycemia, gastrointestinal disturbances, and lactic acidosis. This combination therapy offers a comprehensive approach to glycemic management by targeting multiple pathophysiological defects in type 2 diabetes.